Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627105 | 0.95 | CHRM2 (0.56) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL20964409 | 0.94 | HDAC1 (0.58) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL3145532 | 0.94 | HDAC1 (0.58) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL417948 | 0.90 | TAAR1 (0.61) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002162 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002016 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL29986862 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002036 | 0.83 | CHRM2 (0.58) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL30930046 | 0.83 | CHRM2 (0.58) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002124 | 0.82 | TAAR1 (0.69) | CHRM2CHRM1CHRM3TAAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4873362-A | REACTING AN ACYLOXYACETALDEHYDE WITH AN ALDEHYDE USING AN AMINE AND ACID CATALYST SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | claimed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-5935985-A | Phenoxyacetic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5703099-A | TREATMENT OF THROMBOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASES, GASTRIC ULCER OR HYPERTENSION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0558062-B1 | Phenoxyacetic acid derivatives and pharmaceutical compositions containing them | ONO PHARMACEUTICAL CO (JP) | 1997-05-07 | — | — | EP | disclosed |
| US-5536736-A | CARDIOVASCULAR DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5378716-A | Prostaglandin agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0558062-A2 | Phenoxyacetic acid derivatives and pharmaceutical compositions containing them | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
| US-4873362-A | REACTING AN ACYLOXYACETALDEHYDE WITH AN ALDEHYDE USING AN AMINE AND ACID CATALYST SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
| US-4735937-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| US-4293462-A | Process for the manufacture of enol derivatives, and intermediates | CIBA-GEIGY CORPORATION (US) | 1981-10-06 | — | — | US | disclosed |
| US-4269977-A | Process for the manufacture of 8-oxo-5-thia-1-azabicyclo [4,2,0]oct-2-ene or 3-ene compounds | CIBA-GEIGY CORPORATION (US) | 1981-05-26 | — | — | US | disclosed |
| US-4256739-A | 7β-Amino-3-thio-3-cephem-4-carboxylic acid compounds, and antibacterial compositions and methods using them | CIBA-GEIGY CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4255328-A | CEPHALOSPORINS | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4172832-A | Mercaptoalcohols and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4147864-A | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3932465-A | ANTIBIOTIC | CIBA-GEIGY CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CHRM2 2577/4885CHRM1 2424/4885CHRM3 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.